Resisting resistance
ApoGen's APOBEC3B inhibitors could keep cancer therapies working longer
While many companies are attempting to counteract mutations in cancer that result in resistance, ApoGen Biotechnologies Inc. is instead targeting a mechanism that causes resistance mutations to develop. The approach could prolong responses to cancer therapies.
"As far as we know, we're the only ones that are targeting the underlying mechanisms that cause genomic mutations in tumors," said Thong Le, CEO of Seattle-based incubator Accelerator Corp. ApoGen operates virtually and is managed by the incubator...
BCIQ Target Profiles
Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B)